Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
US drug stocks were shielded from bigger falls in the first quarter by leading coronavirus researchers, leaving groups listed in Japan and Europe to tumble harder.
The coronavirus pandemic wiped billions from global drug stock valuations in the first quarter, with the few gainers failing to offset huge losses elsewhere.
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.